

Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?

Evidence from a meta-analysis including 55 studies

Hong Sun, PhD^a, Tao Li, PhD^a, Rongyuan Zhuang, MD^b, Weimin Cai, PhD^{a,*}, Yuanting Zheng, PhD^{c,*}

Abstract

Background: Renin–angiotensin system inhibitors (RAS inhibitors) are antihypertensive agents with potential antitumor effects. However, various studies have yielded conflicting results on the influence of RAS inhibitors on survival of cancer patients. The aim of this study was to evaluate the effect of RAS inhibitors on recurrence, metastasis, and survival in cancer patients through a metaanalysis.

Methods: PubMed, Web of Science, EMBASE, and Cochrane Library were systematically searched from inception to December 2016. The pooled hazard ratio (HR) with its 95% confidence interval (95% Cl) was calculated to evaluate the association between RAS inhibitors and recurrence, metastasis, and survival in cancer patients.

Results: Fifty-five eligible studies were included in the present meta-analysis. Results showed that there were significant improvements in overall survival (OS) (HR=0.82; 95% CI: 0.77–0.88; P < 0.001), progression-free survival (HR=0.74; 95% CI: 0.66–0.84; P < 0.001), and disease-free survival (HR=0.80; 95% CI: 0.67–0.95; P=0.01) in RAS inhibitor users compared with nonusers. Subgroup analyses revealed that the effect of RAS inhibitors on OS depended on the cancer type or different RAS inhibitors.

Conclusion: This meta-analysis suggests that RAS inhibitors could improve the survival of cancer patients and depend on cancer type and types of RAS inhibitors.

Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, CI = confidence interval, DFS = disease-free survival, DSS = disease-specific survival, HR = hazard ratio, MFS = metastasis-free survival, OS = overall survival, PFS = progression-free survival, RAS = renin–angiotensin system.

Keywords: cancer, meta-analysis, metastasis, recurrence, renin-angiotensin system inhibitors, survival

Editor: Perbinder Grewal.

HS and TL have contributed equally to the article.

Funding/support: The authors thank the National Natural Science Foundation of China (81102459) and Doctoral Fund of Ministry of Education of China (20130071110069) for the support.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

^a Department of Clinical Pharmacy, School of Pharmacy, ^b Department of Medical Oncology, Zhongshan Hospital, ^c State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China.

^{*} Correspondence: Weimin Cai, Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China (e-mail: weimincai@fudan.edu.cn); Yuanting Zheng, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China (e-mail: zhengyuanting@fudan.edu.cn)

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2017) 96:13(e6394)

Received: 19 May 2016 / Received in final form: 17 January 2017 / Accepted: 23 February 2017

http://dx.doi.org/10.1097/MD.00000000006394

1. Introduction

Comorbidities are common in cancer patients, and the phenomenon increases in aging populations.^[1] Hypertension is one of the most common comorbidities in cancer patients. Therefore, the use of antihypertensive agents in these patients may influence survival outcomes. Renin–angiotensin system (RAS) inhibitors are a diverse group of antihypertensive agents that mainly include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).^[2] Recently, several studies suggested that treatment with ACEIs and ARBs is not only effective in cardiovascular diseases, but can also improve cancer progression and survival through mechanisms other than antihypertensive activities.^[3–7]

The RAS plays a critical role in the maintenance of blood pressure, balance of water and electrolytes, cell growth, and the stability of the cardiovascular microenvironment.^[8–11] Over-expressions of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (AT1R), key factors in RAS pathways, have been associated with tumor growth, metastasis, and progression.^[12–15] As a growth factor and main effector factor in RAS, angiotensin II can stimulate tumor neovascularization, which is important for tumor growth.^[16,17] The antitumor mechanisms of RAS inhibitors seem to be biologically reasonable. ACEIs function to reduce the production of angiotensin II to suppress the RAS, and ARBs can selectively

block the action of angiotensin II type I receptors^[18] to inhibit tumor growth, metastasis, and tumor-associated angiogenesis.^[19,20]

Several studies have examined the association between RAS inhibitors and cancer survival. However, the results have remained conflicting even in the same type of cancer. Menter et al^[56] and Wilop et al^[74] reported that the use of RAS inhibitors was associated with improved survival in patients with nonsmall cell lung cancer. However, Aydiner et al^[25] indicated that there was no association between RAS inhibitors and survival in patients with nonsmall cell lung cancer. To help clarify the inconsistent findings, we conducted a meta-analysis of published studies on the association between RAS inhibitors and recurrence, metastasis, and survival in cancer patients.

2. Methods

2.1. Publication search

We performed literature searches in several electronic databases, including PubMed, Web of Science, EMBASE, Cochrane Library, to identify articles on the association between RAS inhibitors and recurrence, metastasis, and survival in cancer patients. We used the following search terms: "Renin-Angiotensin System Inhibitor," or "Angiotensin-Converting Enzyme Inhibitor," or "Angiotensin Receptor Antagonist," or "ARB," or "ACEL," or "RASI," or "ASI," or names of specific RAS inhibitors combined with "neoplasm," or "cancer," or "tumor," or "tumour," or other subtypes/synonyms for cancer and "prognosis," or "prognostic," or "predict," or "predictive," or "prediction," or "morbidity," or "mortality," or "death," or "recurrence," or "recurrent," or "metastasis," or "metastatic," or "survival," or "survive," or "survival analysis." The search terms and strategies are described in detail in Supplementary Table 1, http://links. lww.com/MD/B611. The overall search was limited to human studies and English language publications. Two authors (SH and LT) manually screened the citation lists of retrieved articles independently. All selected studies were checked according to a Newcastle-Ottawa Quality Assessment Scale developed previously.^[21] A high-quality study was judged with a score achieved a rating of ≥ 7 stars.

2.2. Data extraction

Using predefined data summary lists, the information was reviewed and extracted by 2 authors (SH and LT) independently. The detailed information for each study was included as follows: first author, publication year, period of study, country of study, ethnicity, number of patients and cancer types, drug exposure and duration, outcomes, and hazard ratio (HR) estimates method. The survival outcomes, including overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), disease-specific survival (DSS), and metastasis-free survival (MFS), were collected. In addition, the report describing the largest sample size was chosen to be further analyzed when several publications were overlapped. We resolved any discrepancies through discussion.

2.3. Statistical analysis

As a systematic review and meta-analysis, ethical approval of this study is not needed. All statistical analyses were performed using Review Manager 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). The association between RAS inhibitors and survival in cancer patients was estimated by calculating

pooled HRs and related 95% confidence interval (CI). The results are presented in forest plots. The HRs and 95% CIs were extracted according to previously published methods^[22,23] if the articles did not include these data. Study heterogeneity was assessed and presented as χ^2 and I^2 . The fixed effect model was used to estimate pooled HRs if no study heterogeneity existed; otherwise, the random effects model was used. We used funnel plot to assess potential publication bias. An HR < 1 indicated a better outcome for using RAS inhibitors, while HR > 1 indicated a worse outcome for using RAS inhibitors. We considered a P value less than 0.05 to indicate statistical significance. Subgroup analyses were performed for cancer types, ethnicity, and drug types of RAS inhibitors. To assess the quality and consistency of results, sensitivity analysis was performed by deleting each study in turn. Sensitivity analysis was also performed by the extract methods of HRs and study quality (Newcastle-Ottawa Scale (NOS) score).

3. Results

3.1. Study identification

A total of 13,055 studies were collected in the selected databases after removing duplicates (Fig. 1). Seventy-five potential studies were included for full-text view after reviewing the titles and abstracts. With further screening, a total of 55 studies^[24–78] met the inclusion criteria. The main characteristics of the eligible studies are summarized in Table 1. Forty-four studies examined OS, 14 studies examined PFS, 17 studies examined DFS, 9 studies mainly included renal cell carcinoma, lung cancer, colorectal carcinoma, breast cancer, and pancreatic cancer cases. Among the studies that examined OS, 11 studies focused on an Asian population, 33 studies on a Caucasian population, 11 studies examined ARBs, and 12 studies examined ACEIs.

3.2. Qualitative assessment

The quality of eligible studies is shown in Supplementary Table 2, http://links.lww.com/MD/B611. The NOS scores ranged from 6 to 8 stars, with an average NOS score of 6.98. Furthermore, 74.5% of the studies were of high quality with a score that achieved a rating of \geq 7 stars.

3.3. Meta-analysis results

Fifty-five studies that reported survival outcomes were included in the meta-analysis. The results suggested that RAS inhibitors could significantly improve OS (HR=0.82; 95% CI: 0.77–0.88; P < 0.001; Fig. 2), PFS (HR=0.74; 95% CI: 0.66–0.84; P <0.001; Fig. 3), and DFS (HR=0.80; 95% CI: 0.67–0.95; P=0.01; Fig. 4) in cancer patients. Better outcomes in DSS (HR=0.82; 95% CI: 0.63–1.07; P=0.15; Fig. 5) and MFS (HR=0.63; 95% CI: 0.40–1.01; P=0.05; Fig. 6) were observed among RAS inhibitor users compared with nonusers.

We also performed subgroup analyses of the association between RAS inhibitors with OS by cancer types, ethnicity, and drug types of RAS inhibitors (Figs. 7–9). Our results revealed a significantly better outcome in OS among RAS inhibitor users with renal cell carcinoma (HR=0.64; 95% CI: 0.49–0.85; P=0.002), gastric cancer (HR=0.57; 95% CI: 0.38–0.84; P=0.005), pancreatic cancer (HR=0.91; 95% CI: 0.87–0.95; P<0.001), hepatocellular carcinoma (HR=0.59; 95% CI: 0.41–0.86; P=0.007), upper-tract urothelial carcinoma (HR=



Figure 1. Flow diagram of study searching and selection.

0.53; 95% CI: 0.29–0.97; P=0.04), and bladder cancer (HR= 0.36; 95% CI: 0.18-0.72; P=0.004). We also observed better outcome in OS among RAS inhibitor users with rectal/colorectal cancer (HR=0.86; 95% CI: 0.68-1.08; P=0.19), lung cancer (HR=0.89; 95% CI: 0.76-1.05; P=0.17), prostate cancer (HR=0.85; 95% CI: 0.55-1.31; P=0.45), glioblastoma (HR= 0.83; 95% CI: 0.47–1.47; P=0.52), head and neck squamous cell carcinoma (HR=0.38; 95% CI: 0.12-1.20; P=0.10), oropharynx cancer (HR=0.63; 95% CI: 0.38-1.04; P=0.07), and melanoma (HR=0.41; 95% CI: 0.10-1.68; P=0.22). RAS inhibitors did not seem to influence OS in patients with esophageal carcinoma (HR=0.98; 95% CI: 0.80-1.19; P= 0.80), breast cancer (HR = 1.07; 95% CI: 0.91–1.27; P=0.39), and biliary tract cancer (HR = 1.00; 95% CI: 0.73-1.37; P = 1.00). However, there were negative effects on OS in acute myelocytic leukemia (HR = 1.23; 95% CI: 0.94–1.61; P=0.13) and multiple myeloma (HR = 2.01; 95% CI: 1.00-4.05; P=0.05) in RAS inhibitor users compared with nonusers (Fig. 7).

Regarding ethnicity, we observed that ethnicity did not influence the association between RAS inhibitors and survival in cancer patients. With RAS inhibitors use, there was a significant better outcome in OS in cancer patients whether in Asians (HR = 0.82; 95% CI: 0.74–0.91; P < 0.001) or Caucasians (HR = 0.83; 95% CI: 0.76–0.91; *P* < 0.001) (Fig. 8).

We also assessed the effect of drug types of RAS inhibitors on the association between RAS inhibitors and survival in cancer patients. There were 11 studies using ARBs and 12 studies about ACEIs. Results showed that there was a significant improvement in OS among ARB users (HR=0.80; 95% CI: 0.67-0.95; P=0.01), while a little improvement in OS among ACEI users (HR=0.94; 95% CI: 0.85-1.04; P=0.27) (Fig. 9).

3.4. Publication bias

We used Review Manager 5.3 software to analyze the publication bias. The funnel plot was asymmetrical, which suggested that publication bias existed in this meta-analysis (Fig. 10).

3.5. Sensitivity analysis

Sensitivity analysis is shown in Supplementary Table 3, http:// links.lww.com/MD/B611. There was no significant alteration in the pooled HRs (HRs ranging from 0.81 to 0.84) when deleting 1 single study from the overall pooled analysis each time in turn. We also assessed the sensitivity analysis according to the differences of the extraction methods of HRs and study quality (NOS score). The results showed that reported HRs had no significant difference compared with recomputed HRs. There was no significant difference between studies with NOS scores \geq 7 and those with NOS scores <7.

4. Discussion

This meta-analysis was conducted to clarify the effect of RAS inhibitors on survival of cancer patients. Overall, our results

Table 1 Main characteristics (of the studic	es included in m	leta-analysis.					
Reference	Ethnicity	Country	Study period	No. (cases/all)	Tumors	Exposure (ARB/ACEI user no. and duration)	Outcomes	HR estimates
Abouelezz et al ^[24] Aydiner et al ^[25]	Caucasians Caucasians	USA Turkey	NA 2003–2011	94/187 37/117	Hepatocellular carcinoma Nonsmall cell lung cancer	ARB/ACEI 21 pts ARB/16 pts ACEI. At any time after the diamonsis	S0	HR and 95% Cl HR and 95% Cl
Babacan et al ^[26]	Caucasians	Turkey	2005–2012	31/218	Breast cancer	ARB/ACEI. ≥6mo after the initial	OS, DFS	KM
Bardia et al ^[27]	Caucasians	USA	Since 1995	2212/6017	Prostate cancer	diagnosis 2212 pts ARB	OS, DSS	HR and 95% CI
Blute et al ^{izaj}	Caucasians	USA	NA	143/340	Bladder cancer	ARB/ACEI. The time of the first	DFS	HR and 95% CI
Boudreau et al ^[29]	Caucasians	USA	1990-2008	1515/4216	Breast cancer	transurethral resection 1515 pts ACEI	DFS	HR and 95% CI
Buchler et al ^[30]	Caucasians	Xn	1995-2002	25/168	Multiple myeloma	25 pts ACEI	OS, PFS	KM
Cardwell et al ^[31]	Caucasians	Northern Ireland	1998–2006	41 30/20,246	Prostate, colorectal, breast cancer	ARB/ACEI. From cancer diagnosis until	DSS	HR and 95% CI
Chao of al[32]	Conconciono	IICA	1000 2005	160/700	Droot concor	6 mo before cancer-specific death		UD 2004 0607 01
Chae et al ^[33]	Caucasians	ACU	1995-2007	159/1449	breast cancer Breast cancer	And/Acti. Zumu 54 nts ABR/105 nts ACFI	ULS DES DES	HR and 95% CI
Chae et al ^[34]	Caucasians	USA	1999–2013	143/1043	Acute myeloid leukemia	35 pts ARB/ 55 pts ACEI/ 88 pts ARB	0S 0S	HR and 95% CI
						or ACEV2 pts ARB and ACEI		
Chen et al ^[35]	Asians	China	1996–2011	20/141	Esophageal squamous cell carcinoma	15 pts ARB/5 pts ACEI	OS	KM
Derosa et al ⁽³⁶⁾	Caucasians	France	2004–2014	102/213	Renal cell carcinoma	ARB/ACEI. Before, or during treatment	OS, PFS	HR and 95% CI
Engineer et al ^[37]	Caucasians	USA	2000-2009	52/193	Colorectal cancer	(during first month) ARB/ACEI. ≥6mo per any year in the	SO	HR and 95% CI
0						observation period		
Facciorusso et al ⁽³⁸⁾	Caucasians	Italy	2004-2010	80/153	Hepatocellular carcinoma	31 pts ARB/49 pts ACEI	OS, DFS	HR and 95% CI
Failing et al ^[39]	Caucasians	NSA	2011–2014	11/80	Melanoma	ARB/ACEI	OS, PFS	HR and 95% CI
Fujii et al ^[40]	Asians	Japan	2004–2006	76/1163	Breast cancer	ARB/ACEI. ≥6mo after initial diagnosis	DFS	Event and P
Ganz et al ^[41]	Caucasians	USA	1997–2000	409/1779	Breast cancer	409 pts ACEI	OS, DFS, DSS	HR and 95% CI
He et al ^[42]	Caucasians	NSA	1998–2012	350/1174	Esophageal carcinoma	ARB/ACEI	OS, DSS	HR and 95% CI
Holmes et al ^[43]	Caucasians	USA	1985–2005	478/4661	Breast cancer	478 pts ACEI. After diagnosis	OS	HR, 95% CI
Izzedine et al ^[44]	Caucasians	France	2004-2013	105/213	Renal cell carcinoma	ARB/ACEI. Before or during sunitinib	OS, PFS	HR and 95% CI
Januel et al ^[45]	Caucasians	France	2008–2013	26/81	Glioblastoma	19 pts ARB/7 pts ACEI	OS, PFS	KM
Karagiannis et al ^{l46]}	Caucasians	USA	2003–2011	NA/8281	Pancreatic cancer	ARB/ACEI	SO	HR and 95% CI
Keizman et al ¹⁴⁷¹	Caucasians	NSA	2004-2010	44/127	Renal cell carcinoma	ARB/ACEI	OS, PFS	HR and P
Keizman et al ^{r40}	Caucasians	USA, Israel	2004–2013	106/278	Renal cell carcinoma	ARB/ACEI	OS, PFS	HR and 95% Cl
Kim et al ^{red}	Asians	South Korea	2002-2010	30/63	Gastric cancer	20 pts ARB/10 pts ACE	OS, PFS	HR and 95% Cl
Kumekawa et al ^{touj}	Asians	Japan	2007–2011	18/220	Gastric cancer	ARB/ACEI	OS	HR and 95% CI
Lam et al ^{torij}	Caucasians	USA	2005–2013	38/190	Renal cell carcinoma	ARB/ACEI. Before/after TKI	OS	HR and P
Linden et al ^{tozj}	Caucasians	NSA	2010	10/51	Head and neck squamous	ARB/ACEI. During the course of the	OS	Event and P
Mozaniona of a1[53]	Contraction of the	110.0		1050	cell carcinoma	treatment	30	
McKay at al ^[54]	Caucasians		2002-2010	100/10 1027/736	Ulupilalyita calleel Banal call carcinoma	ADD/AUCI. WITGILINI ADD/AUCI. At hasalina ar within		HE and 05% CI
ואטראמץ קו מו	vauvaoiai io			00/+//0+/		30d of study treatment initiation	00, 11,0	
Melhem-Bertrandt et al ^[55]	Caucasians	USA	1995-2007	140/1413	Breast cancer	ARB/ACEI	OS, DFS	HR and 95% CI
Menter et al ^[56]	Caucasians	NSA	2005–2011	351/1813	Nonsmall cell lung cancer	86 pts ARBs/265 pts ACEIs	OS	HR and 95% CI
Miao et al ^[57]	Asians	China	2000–2014	52/301	Nonsmall cell lung cancer	ARB/ACEI	OS, PFS	KM
								(continued)

(continued).								
Reference	Ethnicity	Country	Study period	No. (cases/all)	Tumors	Exposure (ARB/ACEI user no. and duration)	Outcomes	HR estimates
Miyajima et al ^[58] Morris et al ^[59]	Asians Caucasians	Japan USA	1996–2009 1999–2012, 1995–2010	104/557 74/301	Renal cell carcinoma Rectal cancer	ARB/ACEI ARB/ACEI. At the time of the radiation	DSS, MFS OS,MFS,DFS	HR and 95% Cl HR and 95% Cl
Nakai et al ^[60]	Asians	Japan	2001-2013	108/349	Pancreatic cancer	eurisuitation 89 pts ARB/13 pts ACEV5 pts ACEI and ARB/1 nts RI	OS, PFS	HR and P
Nakai et al ^[61]	Asians	Japan	2002-2015	74/287	Biliary tract cancer	61 pts ARB/13 pts ACE	SO	HR and 95% CI
Ole-Petter et al ^[62]	Caucasians	NSA	NA	NA/1120	Renal cell, hepatocellular, GIST	ARB/ACEI	SO	HR and 95% CI
Osumi et al ^[63]	Asians	Japan	2007-2010	104/181	Colorectal cancer	104 pts ARB	OS, PFS	HR and 95% CI
Ranasinghe et al ^[64]	Caucasians	Australia	2003-2007	603/1956	Prostate cancer	603 pts ACEI	DSS	HR and 95% CI
Ronquist et al ^[65]	Caucasians	Sweden	2002-2005	32/62	Prostate cancer	32 pts ACEI. 4-7 d after surgery and	DFS	KM
						continued throughout study		
Sendur et al ^[66]	Caucasians	Turkey	2004-2011	102/486	Breast cancer	102 pts ARB	OS, DFS	OS and DFS value
Sha et al ^[67]	Asians	China	2003-2010	11,207/19,592	Lung cancer	ARB/ACEI. Before diagnosis	OS, PFS	HR and 95% CI
Holmes et al ^[68]	Caucasians	Canada	2004-2008	4279/15,582	Cancer	ARB/ACEI. 1 y before diagnosis	SO	HR and 95% CI
Subgroup1 ^[68]	Caucasians	Canada	2004-2008	880/4019	Breast cancer	ARB/ACEI. 1 y before diagnosis	SO	HR and 95% CI
Subgroup2 ^[68]	Caucasians	Canada	2004-2008	1187/3967	Colorectal cancer	ARB/ACEI. 1 y before diagnosis	SO	HR and 95% CI
Subgroup3 ^[68]	Caucasians	Canada	2004-2008	1256/4241	Lung cancer	ARB/ACEI. 1 y before diagnosis	OS	HR and 95% CI
Subgroup4 ^[68]	Caucasians	Canada	2004-2008	956/3355	Prostate cancer	ARB/ACEI. 1 y before diagnosis	OS	HR and 95% CI
Sorensen et al ^{f69]}	Caucasians	Denmark	1996-2003	5064/18,733	Breast cancer	ARB/ACEI. 0 (no exposure history),	DFS	HR and 95% CI
						1-5, 6-10, and more than 10		
						cumulative years of exposure		
Sorich et al ^[70]	Caucasians	Australia	NA	385/1545	Renal cell carcinoma	247 pts ACEI/123 pts ARB/15 pts	OS, PFS	HR and 95% CI
						ACEI and ARB. When conducting		
L PLA						clinical study (daseline)		
Tanaka et al ^{t/1]}	Asians	Japan	1995-2009	48/279	Upper-tract urothelial carcinoma	43 pts ARB/5 pts ACEI	OS, DSS, MFS	HR and 95% CI
Tuazon et al ^{l/2]}	Caucasians	USA	2004–2008	105/222	Colorectal cancer	ARB/ACEI. ≥3 mo after initial diagnosis	OS, DFS	HR and 95% CI
Misses 24 21[73]		< C			Longe and the longer	מוות וולמוווולווו לימה בני מסרו בי מסח /ו בני מסרו בבין		
wang er ar	Vaucasialis	Acu	1 2 2 0 - 2 0 1 0	142/0/3	NUISINAI CEI IUNG CANCEI	1.30 pts Acet of Arb/4 pts Acet and ARB	Ua, Ura, IMFa	
Wilop et al ^[74]	Caucasians	Germany	1996-2007	52/292	Nonsmall cell lung cancer	9 pts ARB/43 pts ACEI	SO	HR and P
Wong et al ^[75]	Asians	China	2001-2005	22,286/21,7910	Digestive and respiratory cancer	22,286 pts ACEI	SO	HR and 95% CI
Yoshida et al ^[76]	Asians	Japan	1995-2013	56/269	Bladder cancer	ARB/ACEI	OS, DSS	HR and 95% CI
Yoshiji et al ^[77]	Asians	Japan	2004-2006	19/110	Hepatocellular carcinoma	19 pts ACEI. Continuously for 48 mo	DFS	KM
Yuge et al ^[78]	Asians	Japan	1999–2009	51/330	Bladder cancer	46 pts ARB/5 pts ACEI	DFS	HR and 95% CI
ACEI = angiotensin-converting er NA = not available, $OS = overa$	rzyme inhibitor, ARF ill survival, PFS =	3 = angiotensin II recep: progression-free surviv	tor blocker, CI = confidence interval, ral.	DFS = disease-free survi	val, DSS = disease-specific survival, GIST = ga	strointestinal stromal tumor, $HR = hazard ratio, KM = 1$	Kaplan-Meier, MFS = 1	netastasis-free survival,

Sun et al. Medicine (2017) 96:13

Table 1

www.md-journal.com

5

				Hazard Ratio	Hazard Ratio
Study	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Abouelezz, 2013	-0.3567	0.2855	1.2%	0.70 [0.40, 1.22]	
Aydiner, 2015	-0.0101	0.3588	0.8%	0.99 [0.49, 2.00]	
Babacan, 2015	-0.3567	0.2984	1.1%	0.70 [0.39, 1.26]	
Bardia, 2011	-0.3857	0.0639	4.7%	0.68 [0.60, 0.77]	2 4 4
Buchler, 2005	0.7001	0.3562	0.8%	2.01 [1.00, 4.05]	
Chae, 2013	-0.0943	0.2041	2.0%	0.91 [0.61, 1.36]	
Chae, 2014	0.207	0.1377	3.0%	1.23 [0.94, 1.61]	+
Chen. 2014	-0.3147	0.4537	0.6%	0.73 [0.30, 1.78]	
Derosa, 2014	-1.1394	0.2149	1.8%	0.32 [0.21, 0.49]	
Engineer, 2013	-0.0202	0.179	2.3%	0.98 [0.69, 1.39]	
Facciorusso, 2015	-0.661	0.2603	1.4%	0.52 [0.31, 0.86]	
Failing 2016	-0.8916	0.7199	0.2%	0.41 [0.10, 1.68]	
Ganz 2011	0.207	0 2069	1.9%	1 23 [0 82 1 85]	
He 2015	-0.0101	0.1024	3.8%	0.99 [0.81, 1.21]	2
Holmes 2013	-0.1165	0 2012	2.0%	0.89 [0.60 1.32]	
Izzedine 2015	-0.9163	0.2606	1 4%	0.40 (0.24, 0.67)	
Januel 2015	-0.1863	0.2000	1 2%	0.83 [0.47 1.47]	
Karagiannis 2014	-0.0943	0.02002	5 4 %	0.91 [0.97 0.95]	*
Keizman 2011	-0 374	0.0220	1 1 96	0.69 [0.38 1 24]	
Keizman 2014	-0.1165	0.1844	2 7%	0.89 [0.62, 1.24]	
Kim 2012	-0.6033	0.1044	1 2%	0.65 [0.31 0.07]	
Kumekawa 2015	-0.5276	0.235	1 2%	0.50 [0.34, 1.02]	
Lam 2014	-0.5270	0.2012	1.6%	0.53 [0.34, 1.02]	
Linden 2015	-0.0733	0.2004	0.3%	0.38 [0.12, 1.20]	
Magnuson 2014	-0.3070	0.2570	1 496	0.62 (0.29, 1.04)	
Magnuson, 2014	-0.402	0.2373	4 506	0.03 [0.30, 1.04]	-
Molhom Portrandt 2011	-0.1707	0.0037	1 006	0.04 [0.75, 0.50]	
Monter 2016	-0.3147	0.0671	1.6%	0.33 [0.03, 1.31]	+
Mino 2016	-0.3147	0.0071	4.0 %	0.73 [0.04, 0.03]	-
Marrie 2016	-0.1355	0.0080	4.170	0.07 [0.75, 1.04]	
Nokoi 2015	-0.3147	0.2400	2.406	0.73 [0.43, 1.16]	
Nakai, 2015 Nakai 2016	-0.2014	0.17	2.4 70	0.77 [0.55, 1.07]	
Ole Better 2014	0 2107	0.1000	2.0%	0.00 [0.73, 1.37]	
Ole-Feller, 2014	-0.2107	0.1005	3.7 70	0.61 [0.00, 1.00]	
Conduct 2015	-0.4943	0.2282	0.70	0.01 [0.39, 0.95]	
Seriour, 2012	0.0098	0.4031	5.20	1.84 [0.84, 4.05]	
Sila, 2014	-0.1072	0.0350	5.40	0.65 [0.79, 0.91]	
Signy Holmes, 2013	0.0802	0.024	0.4%	1.09[1.04, 1.14]	
Sonch,2016	-0.0305	0.0983	3.9%	0.97 [0.80, 1.18]	
Tanaka, 2012	-0.0349	0.3077	1.170	0.53 [0.29, 0.97]	
10a20fl, 2014	-0.5276	0.4381	0.0%	0.09 [0.20, 1.39]	
Wang, 2015	0.1133	0.1059	3.170	1.12 [0.91, 1.38]	
Worg 2009	-0.5798	0.2683	1.3%	0.56 [0.33, 0.95]	
Wong, 2015	-0.078	0.0249	5.4%	0.92 [0.88, 0.97]	(iz)
Yoshida,2016	-1.0217	0.3537	0.9%	0.36 [0.18, 0.72]	
Total (95% CI)			100.0%	0.82 [0.77, 0.88]	•
Heterogeneity: Tau ² = 0.02	; Chi ² = 192.38, df =	43 (P < 0	.00001); [₽ = 78%	
Test for overall effect: Z = 5	5.43 (P < 0.00001)	- 10475 - 298	1991-1910 (C. 435)		0.05 0.2 1 5 20 RAS Inhibitars better Control better
Figure 2. Forest pl	lot for the association	n betwee	n renin–ar	naiotensin system inhil	bitors and overall survival of cancer patients.

showed that RAS inhibitors could improve survival outcome in cancer patients. For RAS inhibitor users, pooled data showed a significantly better outcome in OS, PFS, and DFS compared with nonusers. In addition, there were better outcomes in DSS and MFS among RAS inhibitor users compared with nonusers.

The mechanisms underlying the effects of RAS inhibitors on the outcome of cancer patients are unclear. Previous studies have established that angiotensin II is involved in promoting the development of cancer. As a powerful mitogen, angiotensin II can promote cell growth and proliferation via transforming growth factor-beta,^[79] tyrosine kinase,^[80] and epidermal growth factor.^[81] Angiotensin II can also regulate cell apoptosis and angiogenesis through upregulating the expression of vascular endothelial growth factor to stimulate neovascularization and Deoxyribonucleic acid synthesis.^[82–84] Angiotensin II/AT1R signaling was found to stimulate cell growth, in part through mammalian target of rapamycin activation.^[85] Furthermore, angiotensin II receptor expression was strongly correlated with tumor aggressiveness and decreased survival in human clear-cell renal cell carcinoma.^[86] Upregulation of ACE enhances cell proliferation and predicts poor prognosis in laryngeal cancer.^[87] Studies indicated that RAS inhibitors could suppress the growth of neoplastic cells and inhibit tumor growth in several tumor models.^[88–91] In addition, RAS inhibitors were reported to inhibit the signal transduction mediated via growth factors through AT1R antagonism^[92] and to suppress cancer cell proliferation through the activation of peroxisome proliferator-activated receptor- γ .^[93]

Interestingly, our findings in subgroup analysis showed that the type of cancer can influence the effect of RAS inhibitors on

Study	Ion[Uazard Datio]	CE.	Weight	Hazard Ratio	Hazard Ratio
Buchler 2005		0.2562	2.5%	2 01 [1 00 4 05]	
Dernes 2014	-0.7985	0.3302	7.0%	0.45 (0.32, 0.63)	
Eailing 2016	-0.7305	0.1755	2.5%	0.67 [0.32, 0.03]	
Pannig, 2010	-0.4003	0.3013	1 0 %	0.65 (0.35, 1.30)	
Janual 2015	-0.3570	0.2567	4.3 /0	0.96 [0.52, 1.42]	
Keizman 2011	-0.6218	0.2307	51%	0.54 [0.35, 0.83]	
Keizman, 2014	-0.462	0.1831	6.6%	0.63 [0.44, 0.90]	
Kim. 2012	-0.1755	0.2661	4.0%	0.84 [0.50, 1.41]	
McKav. 2015	-0.1312	0.0585	13.6%	0.88 [0.78, 0.98]	+
Miao, 2016	-0.4005	0.1293	9.2%	0.67 [0.52, 0.86]	
Nakai, 2015	-0.3567	0.1616	7.5%	0.70 [0.51, 0.96]	
Osumi,2015	-0.4155	0.1804	6.7%	0.66 [0.46, 0.94]	
Sha, 2014	-0.1301	0.0342	14.7%	0.88 [0.82, 0.94]	•
Sorich,2016	-0.1278	0.0953	11.3%	0.88 [0.73, 1.06]	
Total (95% CI)			100.0%	0.74 [0.66, 0.84]	•
Heterogeneity: Tau Test for overall effe	u ^z = 0.02; Chi ^z = 37.61, (ect: Z = 4.77 (P < 0.0000	df = 13 (P)1)	= 0.0003	i); l² = 65%	0.1 0.2 0.5 1 2 5 10 RAS Inhibitors better Control better

				Hazard Ratio	Hazard Ratio
Study	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Babacan, 2015	-0.3285	0.3828	3.6%	0.72 [0.34, 1.52]	
Blute, 2015	-0.4943	0.1552	8.1%	0.61 [0.45, 0.83]	
Boudreau, 2014	-0.1393	0.0826	9.9%	0.87 [0.74, 1.02]	+
Chae, 2011	-0.7133	0.2336	6.2%	0.49 [0.31, 0.77]	
Chae, 2013	-0.2107	0.2069	6.8%	0.81 [0.54, 1.22]	
Facciorusso, 2015	-0.4788	0.2494	5.8%	0.62 [0.38, 1.01]	
Fujii, 2012	0.4318	0.3342	4.2%	1.54 [0.80, 2.96]	
Ganz, 2011	0.4447	0.2168	6.6%	1.56 [1.02, 2.39]	
Melhem-Bertrandt, 2011	-0.1985	0.2131	6.6%	0.82 [0.54, 1.25]	
Morris,2016	-0.2744	0.5095	2.3%	0.76 [0.28, 2.06]	
Ronquist, 2009	-1.204	0.5605	2.0%	0.30 [0.10, 0.90]	· · · · · · · · · · · · · · · · · · ·
Sendur, 2012	0.0296	0.269	5.4%	1.03 [0.61, 1.75]	
Sorensen, 2013	0.1082	0.0707	10.2%	1.11 [0.97, 1.28]	+
Tuazon, 2014	-0.821	0.2684	5.4%	0.44 [0.26, 0.74]	
Wang, 2015	0.0296	0.1226	9.0%	1.03 [0.81, 1.31]	+
Yoshiji, 2011	-0.1985	0.406	3.3%	0.82 [0.37, 1.82]	
Yuge, 2012	-0.821	0.3114	4.6%	0.44 [0.24, 0.81]	
Total (95% CI)			100.0%	0.80 [0.67, 0.95]	•
Heterogeneity: Tau ² = 0.0	7; Chi² = 52.24, df = 1	6 (P < 0.0	0001); I ^z =	69%	
Test for overall effect: Z =	2.52 (P = 0.01)				RAS Inhibitors better Control better

Study	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI	IV. Random, 95% Cl
Bardia, 2011	-0.755	0.1652	14.1%	0.47 [0.34, 0.65]	
Cardwell,2014	-0.1054	0.0413	17.7%	0.90 [0.83, 0.98]	•
Chae, 2013	-0.1919	0.2357	11.5%	0.83 [0.52, 1.31]	
Ganz, 2011	0.239	0.2756	10.2%	1.27 [0.74, 2.18]	
He, 2015	-0.0619	0.1246	15.6%	0.94 [0.74, 1.20]	-
Miyajima, 2015	-0.9889	0.9847	1.7%	0.37 [0.05, 2.56]	
Ranasinghe, 2013	0.5481	0.174	13.8%	1.73 [1.23, 2.43]	
Tanaka, 2012	-0.7985	0.3651	7.7%	0.45 [0.22, 0.92]	
Yoshida,2016	-0.755	0.3646	7.7%	0.47 [0.23, 0.96]	
Total (95% CI)			100.0%	0.82 [0.63, 1.07]	•
Heterogeneity: Tau ² :	= 0.10; Chi ² = 38.90, (df = 8 (P	< 0.00001); I ² = 79%	

Figure 5. Funnel plot of the association between renin-angiotensin system inhibitors and disease-specific survival of cancer patients.



survival of patients. Improvement of survival was found in renal cell carcinoma, gastric cancer, pancreatic cancer, hepatocellular carcinoma, upper-tract urothelial carcinoma, and bladder cancer patients in RAS inhibitor users. In addition, a better trend of outcome was observed in rectal/colorectal cancer, lung cancer, prostate cancer, glioblastoma, head and neck squamous cell carcinoma, oropharynx cancer, and melanoma with RAS inhibitor use, although there was no statistical significance. Conversely, the RAS inhibitors showed negative effects in patients with acute myelocytic leukemia or multiple myeloma. The mechanisms underlying the different impacts of RAS inhibitors in various cancer types are poorly understood.

Angiogenesis is a complex physiological process and can be disrupted by several mechanisms: interrupting the signaling pathways, inhibiting endothelial cells, or inhibiting other activators of angiogenesis. This strategy to target angiogenesis has provided therapeutic benefit in several types of cancer and led to the Food and Drug Administration approval of antiangiogenic agents in the treatment of renal, nonsmall cell lung, and colon cancers.^[92] In addition, therapies that target new blood vessel formation are an emerging and promising area of research in prostate, hepatocellular, gastric, and bladder cancer.^[94–97] We speculate that the different responses to antiangiogenesis therapy in various types of cancer may partly explain our results showing that RAS inhibitors have different influences in different types of tumors.

Why may the types of RAS inhibitors influence the association between RAS inhibitors and survival in cancer patients? There was significant improvement in OS among ARB users, while there was little improvement in OS among ACEI users. However, only 11 and 12 studies focused on ARBs and ACEIs, respectively, and the different cancer types may influence the results. Therefore,

		the second s	Contraction of the second				and the second	the second second second		
				- Bardia, 2011	-0.3857	0.0639	4.2%	0.68 [0.60, 0.77]		
-1.1394 0.2	149 1.9%	0.32 (0.21, 0.49)		Signy Holmes 2013	0.0593	0.0812	3.0%	1 06 10 90 1 241		
-0.9163 0.2	606 1.5%	0 40 10 24 0 671		Support Children Chil	0.0303	0.0012	3.5%	1.00 [0.50, 1.24]		
.0 374 0 2	989 1.2%	0.69 (0.38, 1.24)		Subtotal (95% CI)			8.2%	0.85 [0.55, 1.51]		
01165 01	844 2.2%	0 89 10 62 1 28		Heterogeneity: Tau ^a = 0.09; Chi ^a = 18.46,	df = 1 (P <	0.0001); P	= 95%			
0.0722 0.2	204 1.6%	0.61 (0.22, 0.02)		Test for overall effect: Z = 0.75 (P = 0.45)						
0.1707 0.0	507 416	0.01 [0.32, 0.02]								
-0,1707 0.0	4,130	0.64 [0.73, 0.80]		A succe second and facebooking						
-0.0305 0.0	983 3.6%	0.91 10.80, 1.181		Acute myeloid leukernia		1.111		The second second second second		
	10.1%	0.64 [0.49, 0.85]	-	- Chae, 2014	0.207	0.1377	2.9%	1.23 [0.94, 1.61]		1-
33.54, df = 6 (P < 0.00	001); P= 82%			Subtotal (95% CI)			2.9%	1.23 [0.94, 1.61]		-
= 0.002)				Heterogeneity Not applicable						
				Test for everall effect 7 = 1.50 /P = 0.12)						
				restion overall ellect 2 = 1.50 (F = 0.15)						
-0.0202 0	179 2.3%	0.98 [0.69, 1.39]								
-0.3147 0.2	468 1.6%	0.73 [0.45, 1.18]		Glioblastoma						
-0.4943 0.2	282 1.7%	0 61 10 39, 0 951		- Januel 2015	-0 1863	0 2902	1.2%	0.8310.47.1.471		
0.0296 0.0	521 4.4%	1.03 (0.93, 1.14)	+	Subtotal (95% CI)			4 25	0.83 10 47 1 471	-	
-0 5276 0 4	381 0.6%	0.59 (0.25, 1.39)		Subtout (Solid City			1.4.10	0.00 [0.41, 1.41]		
	10.7%	0.86 (0.68, 1.08)	•	Heterogeneity: Not applicable						
7 99 41- 4 (9 - 0.09)	18-50%	and farmer unof	-	Test for overall effect: $Z = 0.64$ (P = 0.52)						
0.10	1 - 30 4									
- 0.10/				Head and neck squamous cell ca	rcinoma					
				Linden 2016	0.0070	0.0004	0.400		-	
				- Linden, 2015	-0.3018	0.5881	0.4%	0.38 [0.12, 1.20]		
-0.0101 0.3	588 0.9%	0.99 [0.49, 2.00]		Subtotal (95% CI)			0.4%	0.38 [0.12, 1.20]		
-0.3147 0.0	6/1 4.2%	0.73 [0.64, 0.83]		Heterogeneity: Not applicable						
-0.1393 0.0	895 3.8%	0.87 [0.73, 1.04]		Test for overall effect Z = 1.65 (P = 0.10)						
-0.1672 0.0	356 4.6%	0.85 [0.79, 0.91]		restrict eretail energy - 1.00 (r - 0.10)						
0.1044 0.0	382 4.6%	1.11 [1.03, 1.20]	-							
0.1133 0.1	059 3.5%	1.12 [0.91, 1.38]	+-	Multiple myeloma						1000
-0.5798 0.2	683 1.4%	0.56 [0.33, 0.95]		- Buchler, 2005	0.7001	0.3562	0.9%	2.01 [1.00, 4.05]		
	22.9%	0.89 [0.76, 1.05]	•	Subtotal (95% CI)			0.9%	2.01 [1.00, 4.05]		
4877 df= 6 (P + 0.00	001) 1 = 88%	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Listeresee eits blet evelle shie						and a second second
=0.17)				Heterogeneny. Not applicable						
				Test for overall effect Z = 1.97 (P = 0.05)						
0 3567 0 3		0 20 10 20 1 201		Oropharynx cancer						
-0.3307 0.2	204 1.270	0.70 [0.39, 1.20]		Magnuson 2014	0.462	0.2570	1.5%	0 6 2 10 20 1 0 41		-
-0.0943 0.2	041 2.0%	0.91 [0.01, 1.30]		magnuson, 2014	-0.402	0.2575	1,5%	0.03 [0.36, 1.04]	-	
0.207 0.2	069 2.0%	1.23 [0.82, 1.85]		Subtotal (95% CI)			1.0%	0.63 [0.38, 1.04]		
-0.1165 0.2	012 2.0%	0.89 [0.60, 1.32]		Heterogeneity: Not applicable						
-0.0101 0.2	147 1.9%	0.99 [0.65, 1.51]		Test for overall effect Z = 1.79 (P = 0.07)						
0.6098 0.4	031 0.7%	1.84 [0.84, 4.05]								
0.1989 0.0	814 3.9%	1.22 [1.04, 1.43]	-	Upper tract wethelial carelooms						
	13.7%	1.07 [0.91, 1.27]	•	opper-tract uromenal carcinoma			1.00			
7.98, df = 6 (P = 0.24)	I*= 25%			 Tanaka, 2012 	-0.6349	0.3077	1,1%	0.53 [0.29, 0.97]		
= 0.39)				Subtotal (95% CI)			1,1%	0.53 [0.29, 0.97]		-
				Heterogeneity: Not applicable						
				Test for suprall effect 7 = 2.06 /P = 0.04)						
-0.6033 0.2	854 1.3%	0.55 (0.31, 0.96)		restion overall effect. 2 = 2.00 (F = 0.04)						
0.5276 0.2	912 1.2%	0 59 10 24 1 021								
.0.5210 0.4	2.65	0 57 10 38 0 941	-	Melanoma						
0.01 -1 -0 -0.05	R - 00	orgy forgot growt		- Failing 2016	-0.8916	0.7199	0.3%	0.41 (0.10.1.68)	-	
0.04, 01=1 (P=0.05)	P = 0.96			Subtotal (95% CI)			0.3%	0.4110.10.1.681	-	
0.005)				Suprotal (No. 4 Cit			0.070	order for the strend		
				Heterogeneny: Not applicable						
10000				Test for overall effect Z = 1.24 (P = 0.22)						
-0.0943 0.0	229 4.7%	0.91 [0.87, 0.95]								
-0.2614	17 2.4%	0.77 [0.55, 1.07]		Biliary tract cancer						
	7.2%	0.91 [0.87, 0.95]		history 2040	0	0 4000	2.00	1 00 10 70 1 071	_	
0.95, df=1 (P=0.33)	P= 0%			- Nakal,2016	0	0.1000	2.0%	1.00 [0.73, 1.37]		-
(0.0001)				Subtotal (95% CI)			2.0%	1.00 [0.73, 1.37]		
				Heterogeneity: Not applicable						
				Test for overall effect, Z = 0.00 (P = 1.00)						
-0.3147 0.4	537 0.6%	0.73 [0.30, 1.78]								
-0.0101 0.1	024 3.5%	0.99 (0.81, 1.21)	+	Diaddasaaaaaa						
and the second second	4.1%	0.98 [0.80, 1.19]	•	bladder cancer	144475		1.1.1.1	in the second second		
0.43 df=1 (P=0.61)	P= 0%			 Yoshida,2016 	-1.0217	0.3537	0.9%	0.36 [0.18, 0.72]		
0.90)				Subtotal (95% CI)			0.9%	0.36 [0.18, 0.72]		
				Heterogeneity Not applicable						
				Toot for everall effect 7 = 2 00 m = 0.00 m	c					
				rest for overall effect Z = 2.89 (P = 0.004)						
-0.3567 0.2	855 1,3%	0.70 [0.40, 1.22]								
-0.661 0.2	603 1.5%	0.52 [0.31, 0.86]		Total (95% CI)			100.0%	0.84 [0.78, 0.91]		
	2.7%	0.59 [0.41, 0.86]	-	Internet Test and and and		- 0.0000	11 12 - 700		1 1 1	
				Helpronenelly I still a little water and						
0.62, df=1 (P=0.43)	P= 0%			Heterogeneity: Tau* = 0.03, Chi* = 184.36	, di = 44 (r	* 0.0000	1), 1 = 703	0 (1.1 0.2 0.5	1 2 5 1
	-0.9183 02 -0.9183 02 -0.1166 01 -0.1166 01 -0.0137 02 -0.0305 00 33.54, df = 6 (P = 0.00) -0.0202 0 -0.0202 0 -0.0202 0 -0.0207 02 -0.444 02 -0.0276 04 -0.0276 04 -0.0276 04 -0.0276 04 -0.0276 02 -0.044 02 -0.1167 02 -0.044 00 -0.1172 00 -0.1187 02 -0.044 0 -0.1187 02 -0.044 0 0.1133 01 -0.1187 02 -0.044 0 0.1133 01 -0.1187 02 -0.044 0 0.1133 01 -0.1186 02 -0.0043 02 -0.0043 02 -0.0043 02 -0.0281 02 -0.0281 02 -0.0281 02 -0.0281 02 -0.010 01 -0.3147 04 -0.0387 02 -0.04 df 1 (P = 0.85), -0.04 df 1 (P = 0.33), -0.010 01 -0.3147 04 -0.010 01 -0.3567 02 -0.010 02	-0.9163 0.2806 1.5% -0.9163 0.2806 1.5% -0.1165 0.1846 1.2% -0.1165 0.1846 1.2% -0.0170 0.1847 1.2% -0.0305 0.0983 1.6% 33.54, era 6 (P < 0.0001), P < 82% -0.0305 0.0983 1.6% -0.147 0.2468 1.6% -0.130 0.022 1.7% -0.9167 0.0351 0.2% -0.1672 0.0351 0.2% -0.1672 0.0352 1.2% -0.1672 0.0352 1.2% -0.1672 0.0352 1.2% -0.1672 0.032 4.6% 0.113 0.1632 4.6% 0.113 0.1632 4.6% 0.113 0.1632 4.6% -0.114 0.032 4.6% -0.113 0.1632 4.5% -0.1672 0.0354 1.2% -0.043 0.0241 1.3% -0.053 0.264 1.3% -0.053 0.2654 1.3% -0.053 0.2654 1.3% -0.053 0.2654 1.3% -0.053 0.2654 1.3% -0.053 0.2654 1.3% -0.050 0.2674 0.5% -0.0161 0.959, P = 0% -0.0161 0.127 1.5% 0.030 0.2654 0.27 2.6% -0.0161 0.217 1.5% 0.033 0.2654 1.3% -0.0261 0.227 0.5% -0.0161 0.127 1.5% -0.0161 0.217 1.	-0.9453 0.2066 1.5% 0 40 [3.2, 0.67] -0.374 0.2066 1.2% 0 40 [3.2, 0.67] -0.372 0.298 1.2% 0.69 [3.8, 1.24] -0.035 0.9993 1.2% 0.69 [3.8, 1.24] -0.035 0.9993 1.2% 0.99 [3.2, 1.28] -0.035 0.9993 1.6% 0.37 [3.6, 1.19] -0.035 0.9993 1.6% 0.37 [3.6, 1.19] -0.347 0.2469 1.6% 0.27 [3.6, 1.19] -0.347 0.2569 0.5% 0.5% 0.59 [3.7, 0.91] -0.146 0.205 1.4% 0.27 [3.6, 1.28] -0.147 0.057 1.2% 0.27 [3.6, 0.5] -0.147 0.057 1.2% 0.29 [3.6, 1.39] -0.147 0.057 1.2% 0.29 [3.6, 1.39] -0.147 0.057 1.2% 0.29 [3.6, 1.39] -0.140 0.2569 0.5% 0.59 [3.6, 0.5] -0.147 0.057 1.2% 0.29 [3.6, 1.39] -0.147 0.057 1.2% 0.59 [3.7, 0.9] -0.145 0.212 2.0% 0.68 [3.7, 0.9] -0.044 0.204 1.2% 0.7 [3.6, 1.2] -0.041 0.217 1.5% 0.58 [3.7, 0.9] -0.044 0.214 1.2% 0.7 [3.6, 1.2] -0.041 0.217 1.5% 0.58 [3.7, 0.9] -0.041 0.217 1.5% 0.58 [3.6, 1.2] -0.041 0.217 1.5% 0.59 [3.6, 1.2] -0.041 0.177 1.5% 0.59 [3.6, 1.2] -0.041 0.177 1.5% 0.59 [3.6, 1.2] -0.041 0.177 1.5% 0.59 [3.6, 1.2] -0.050 0.05 0.05 0.5% 0.25% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.	-0.9183 0.2006 1.5% 0.40 [3,2,4,67] -0.974 0.2086 1.2% 0.69 [3,2,4,24] -0.919 0.281 1.5% 0.69 [3,2,4,24] -0.919 0.923 1.5% 0.69 [3,2,4,24] -0.919 0.993 3.5% 0.67 [3,2,0,119] -0.916 0.993 3.5% 0.67 [3,0,119] -0.917 0.2468 1.5% 0.72 [3,6,119] -0.917 0.259 0.5% 0.99 [3,6,01] -0.917 0.959 0.5% 0.99 [3,6,01] -0.917 0.959 0.5% 0.99 [3,6,01] -0.917 0.959 0.5% 0.99 [3,6,01] -0.147 0.959 0.5% 0.99 [3,6,01] -0.147 0.959 0.5% 0.99 [3,6,01] -0.147 0.959 0.5% 0.99 [3,6,01] -0.147 0.959 0.5% 0.99 [3,6,12] -0.147 0.959 0.5% 0.99 [3,6,12] -0.147 0.959 0.5% 0.99 [3,6,12] -0.147 0.959 0.5% 0.99 [3,6,12] -0.147 0.959 0.9% 0.99 [3,6,12] -0.147 0.959 0.9% 0.99 [3,6,12] -0.147 0.959 0.9% 0.99 [3,6,15] -0.147 0.959 0.9% 0.99 [3,6,15] -0.145 0.212 0.0% 0.91 [3,1,19] -0.357 0.2044 1.2% 0.70 [3,9,12] -0.950 0.2041 1.2% 0.70 [3,9,12] -0.900 0.2041 1.2% 0.70 [3,9,12] -0.900 0.2041 1.2% 0.71 [3,0,09] -0.377 0.90 0.95 1.10 [0.90 [3,0,17] -0.950 0.2041 1.2% 0.71 [3,0,09] -0.377 0.90 0.9% 1.22 [1,0,09] -0.377 0.90 0.9% 1.22 [1,0,09] -0.377 0.90 0.9% 1.22 [1,0,09] -0.377 0.90 0.9% 1.22 [1,0,09] -0.377 0.90 0.9% 1.22 [1,0,09] -0.347 0.9231 1.3% 0.59 [3,1,09] -0.900 0.90 0.9% 1.20 [3,0,07] -0.916 0.9232 4.7% 0.91 [3,0,17] -0.950 0.90 0.9% 1.20 [3,0,09] -0.917 0.923, 1.5% 0.99 [3,0,17] -0.950 0.90 0.9% 1.20 [3,0,09] -0.917 0.923, 1.5% 0.91 [3,0,09] -0.917 0.923, 1.5% 0.91 [3,0,09] -0.917 0.923 1.7% 0.91 [3,0,09] -0.916 0.923 1.7% 0.91 [3,0,09] -0.917 0.923 1.7% 0.91 [3,0,017] -0.916 0.923 1.7% 0.91 [3,0,017] -0.916 0.923 1.7% 0.91	-0.948 0.2066 1.5% 0.40 [2.4, 0.67] -0.948 0.2066 1.5% 0.69 [3.6, 1.28] -0.948 0.2066 1.5% 0.69 [3.6, 1.28] -0.045 0.0981 1.5% 0.69 [3.6, 1.28] -0.035 0.0981 3.5% 0.69 [3.6, 1.28] -0.030 0.0981 3.5% 0.49 [3.2, 1.28] -0.030 0.0981 3.5% 0.49 [3.2, 1.28] -0.030 0.0981 3.5% 0.49 [3.2, 1.28] -0.030 0.0981 3.5% 0.29 [3.6, 1.38] -0.030 0.0981 3.5% 0.59 [3.6, 1.38] -0.0420 0.028 0.0951 4.4% 10 [3.3, 1.48] -0.347 0.2468 1.6% 0.72 [3.4, 1.18] -0.347 0.2468 1.6% 0.72 [3.4, 1.18] - -0.347 0.057 1.22% 0.78 [0.46, 1.38] -0.146 0.0328 0.6% 1.28] - -0.157 0.058 0.5% 0.07 [3.23% 0.58 [3.7, 1.68] -0.147 0.057 1.22% 0.27 [3.6, 0.68] [3.7, 1.68] -0.147 0.058 0.5% 0.128 [3.7, 1.68] - -0.157 0.058 0.5% 0.128 [3.7, 1.68] - -0.147 0.058 0.5% 0.27 [3.7, 0.8] [3.7, 1.68] - -0.147 0.058 0.5% 0.27 [3.7, 0.8] [3.7, 1.58] - -0.150 0.058 0.5% 0.128 [3.7, 1.58] - -0.150 0.058	-0.9180 0.2006 1.5% 0.040 2.6, 071 -0.917 0.924 1.5% 0.040 2.6, 071 -0.9180 0.200 0.918 1.2% 0.90 0.918 1.2% -0.9180 0.2014 2.5% 0.90 0.81, 2.0 0.91	-0.912 0.206 1.58 0.60 0.005	-0.918 0.2009 1.5% 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009 0.018 0.2009	-0.010 2.000 1.55 0.000 2.24 0.220 0.220 0.220 0.2	-0.910 0.920 0.921 <t< td=""></t<>

Figure 7. Forest plot for the subgroup analysis of cancer types.

Cubaroup	log[Harard Datio]	CE.	Moight I	Hazard Ratio	Hazard Ratio
Acian	ioginazaru katioj	JE.	weight	Nanuom, 95% CI	IV, Randoll, 55% CI
Chen 2014	-0.2147	0.4527	0.6%	0 72 10 20 1 701	
kim 2012	-0.5147	0.4337	1 296	0.55 (0.30, 1.70)	
Kumekawa 2015	-0.0033	0.233	1.2%	0.59 [0.34 1 02]	
Miao 2016	-0.1393	0.0895	4 1 96	0.87 [0.73 1.04]	-
Nakai 2015	-0.2614	0.0000	2.4%	0.77 [0.55 1.07]	
Nakai 2016	0.2014	0 1606	2.4%	1 00 0 73 1 371	
Osumi 2015	SVDV 0-	0.2282	1.7%	0.61 (0.30, 0.05)	
Sha 2014	-0.4545	0.0356	5.2%	0.85 (0.70, 0.01)	
Tanaka 2012	-0.6349	0.3077	1 1 96	0.63 [0.73, 0.31]	
Wong 2015	-0.0343	0.0077	5.4%	0.03 [0.23, 0.37]	
Vochida 2016	-1.0217	0.0243	0.4%	0.36 (0.18, 0.72)	· · · · · · · · · · · · · · · · · · ·
ubtotal (95% CI)	-1.0217	0.3337	26.3%	0.82 [0.74, 0.04]	•
atorogonoity: Tour = 0.01: Ch	i2-22.00 df-10/P-	- 0.01\.13	- 56%	0.02 [0.14, 0.51]	
est for overall effect: Z = 3.88	(P = 0.0001)	- 0.01),1	- 30 %		
Caucasian Abouelett 2012	0.2567	0 2055	1.20	0 70 10 40 4 201	
Audinor 2015	-0.3567	0.2899	0.000	0.70 [0.40, 1.22]	
Ayumer, 2015 Roboson, 2015	-0.0101	0.3588	1.40	0.99 [0.49, 2.00]	
Babacan, 2015	-0.3567	0.2984	1.1%	0.70 [0.39, 1.26]	-
Bardia, 2011	-0.3857	0.0639	4.7%	0.68 [0.60, 0.77]	
Buchler, 2005	0.7001	0.3562	0.8%	2.01 [1.00, 4.05]	
Chae, 2013	-0.0943	0.2041	2.0%	0.91 [0.61, 1.36]	
Chae, 2014	0.207	0.1377	3.0%	1.23 [0.94, 1.61]	
Derosa, 2014	-1.1394	0.2149	1.8%	0.32 [0.21, 0.49]	
Engineer, 2013	-0.0202	0.179	2.3%	0.98 [0.69, 1.39]	and the second se
Facciorusso, 2015	-0.661	0.2603	1.4%	0.52 [0.31, 0.86]	
Failing, 2016	-0.8916	0.7199	0.2%	0.41 [0.10, 1.68]	
Ganz, 2011	0.207	0.2069	1.9%	1.23 [0.82, 1.85]	T
He, 2015	-0.0101	0.1024	3.8%	0.99 [0.81, 1.21]	T
Holmes, 2013	-0.1165	0.2012	2.0%	0.89 [0.60, 1.32]	
Izzedine, 2015	-0.9163	0.2606	1.4%	0.40 [0.24, 0.67]	
Januel, 2015	-0.1863	0.2902	1.2%	0.83 [0.47, 1.47]	
Karagiannis, 2014	-0.0943	0.0229	5.4%	0.91 [0.87, 0.95]	*
Keizman, 2011	-0.374	0.2989	1.1%	0.69 [0.38, 1.24]	
Keizman, 2014	-0.1165	0.1844	2.2%	0.89 [0.62, 1.28]	
Lam, 2014	-0.6733	0.2394	1.6%	0.51 [0.32, 0.82]	
Linden, 2015	-0.9676	0.5881	0.3%	0.38 [0.12, 1.20]	
Magnuson, 2014	-0.462	0.2579	1.4%	0.63 [0.38, 1.04]	
McKay, 2015	-0.1767	0.0697	4.5%	0.84 [0.73, 0.96]	-
Melhem-Bertrandt, 2011	-0.0101	0.2147	1.8%	0.99 [0.65, 1.51]	
Menter,2016	-0.3147	0.0671	4.6%	0.73 [0.64, 0.83]	-
Morris,2016	-0.3147	0.2468	1.5%	0.73 [0.45, 1.18]	
Ole-Petter, 2014	-0.2107	0.1065	3.7%	0.81 [0.66, 1.00]	*
Sendur, 2012	0.6098	0.4031	0.7%	1.84 [0.84, 4.05]	
Signy Holmes, 2013	0.0862	0.024	5.4%	1.09 [1.04, 1.14]	
Sorich,2016	-0.0305	0.0983	3.9%	0.97 [0.80, 1.18]	+
Tuazon, 2014	-0.5276	0.4381	0.6%	0.59 [0.25, 1.39]	S
Wang, 2015	0.1133	0.1059	3.7%	1.12 [0.91, 1.38]	+
Wilop, 2009	-0.5798	0.2683	1.3%	0.56 [0.33, 0.95]	
ubtotal (95% CI)		and the second second	73.7%	0.83 [0.76, 0.91]	•
eterogeneity: Tau² = 0.04; Ch est for overall effect: Z = 3.93	i² = 163.88, df = 32 (F (P < 0.0001)	< 0.000	01); I ² = 809	%	
otal (05% CI)			100.0%	0 82 [0 77 0 99]	•
eterogeneity Tous - 0.02 Ch	F- 102 29 df- 42 /0	< 0.000	01) 12 - 700	x.	
eterogeneity. rau* = 0.02; Ch	r = 192.30, ut = 43 (P)	~ 0.000	01), F = 785	70	0.01 0.1 1 10 100
strior overall effect. $\angle = 0.43$	(r < 0.00001) Chiz=0.04 df=4 (D	- 0.94	2-0%		RAS Inhibitors better Control better
scion suburoub dilierences.	China 0.04. 01 = 1 (P	- 0.64). I	= 0.%		of otherioity
	Figure 8.	orest pl		subyroup analysis (JI EUTITIOILY.

more studies are needed to investigate the impact of different drug types of RAS inhibitors on cancer survival.

Some limitations of our meta-analysis should be considered. For example, we only included the published studies. Therefore, the publication bias may influence the results of our metaanalysis. We only searched specific databases, which may have left out some studies in other databases. In addition, some relevant studies could not be included in our meta-analysis due to publication limitations or incomplete raw data. Furthermore, the search strategies were limited to English language publications; therefore, some studies were not be included in our meta-analysis.

Nevertheless, the meta-analysis was carried out at an appropriate time to clarify the association between RAS inhibitors and recurrence, metastasis, and survival of cancer patients. Multiple strategies and strict criteria were applied to identify and include the studies and subgroup analyses to reveal the factors that may influence the association between RAS inhibitors and cancer survival. To our knowledge, only 2 published meta-analyses have reported the association between

Subaroup log(Hazard Ratio) SE Weight IV. Random, 95% CI IV. Random, 95% CI ARBs						Hazard Ratio			Hazard Ratio		
ARBs Aydiner, 2015 - 0.0101 0.3568 1.3% 0.99 [0.49, 2.00] Bardia, 2011 - 0.3857 0.0639 10.2% 0.68 [0.60, 0.77] Chae, 2013 - 0.5352 0.395 1.1% 0.59 [0.27, 1.27] Factorusso, 2015 - 0.9648 0.2803 2.1% 0.38 [0.22, 0.66] Chargiannis, 2014 - 0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 - 0.4943 0.2282 2.9% 0.61 [0.38, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 - 0.1054 0.1488 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 - 0.0202 0.1503 5.2% 0.89 [0.73, 1.32] biotal (95% CI) ACEIs Buchier, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 0.66 [0.42, 1.04] Factorusso, 2015 - 0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Lam, 2014 - 0.1654 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 - 0.1654 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 - 0.6539 0.232 2.8% 0.52 [0.33, 0.82] Lam, 2015 - 0.078 0.0249 12.6% 0.92 [0.83, 1.30] Tuazon, 2014 - 0.8538 0.5097 0.7% 0.43 [0.16, 1.48] Wong, 2015 - 0.078 0.0249 12.6% 0.92 [0.88, 0.97] biotal (95% CI) 5.7% 0.94 [0.85, 1.04] Wong, 2015 - 0.078 0.0249 12.6% 0.92 [0.88, 0.97] biotal (95% CI) 5.7% 0.94 [0.85, 1.04] Herogeneity: Tau ² = 0.01; Chi ² = 825, dif = 22 (P < 0.00001); I ² = 68% st for overall effect Z = 1.11 (P = 0.27) tal (95% CI) 5.7% 0.94 [0.85, 1.04] Facs Inhibitors better Control better Facs Inc. Concer bet the curvitore matching disc the properties can be the disc the properties can be the disc the properties the properties can be the disc the properties the properist can be the dis the properties the properimeter and the prope		Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% CI		IV, I	Random, 95% (
Aydiner, 2015 - 0.0101 0.3568 1.3% 0.99 [0.49, 2.00] Bardia, 2011 - 0.3857 0.0639 10.2% 0.66 [0.60, 0.77] Factorusso, 2015 - 0.9648 0.2803 2.1% 0.38 [0.22, 0.66] Karagiannis, 2014 - 0.0834 0.0344 12.1% 0.92 [0.86, 0.98] Lam, 2014 - 0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 - 0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 - 0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuzzon, 2014 0.3918 0.5325 0.6% 1.48 [0.52, 4.21] Wang, 2015 - 0.0202 0.1503 5.2% 0.98 [0.73, 1.32] btotal (95% Cl) 44.3% 0.80 [0.67, 0.95] Holmes, 2015 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0966 0.2323 2.8% 1.10 [0.70, 1.74] Factorusso, 2015 - 0.0202 0.1503 5.2% 0.98 [0.60, 1.32] ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0966 0.2323 2.8% 1.00 [0.70, 1.74] Factorusso, 2015 - 0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 - 0.1165 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2014 - 0.1054 0.0292 12.4% 0.90 [0.86, 0.95] Lam, 2014 - 0.155 0.2306 2.8% 0.98 [0.60, 1.32] Linden, 2015 - 0.0776 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuzzon, 2014 - 0.0353 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 - 0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.778 0.0249 12.6% 0.92 [0.88, 0.97] Wang, 2015 - 0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.778 0.0249 [1.26% 0.92 [0.88, 0.97] total (95% Cl) 5.0.778 0.0249 12.6% 0.92 [0.88, 0.97] total (95% Cl) 5.0.778 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.716 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.716 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.716 0.0249 12.6% 0.92 [0.88, 0.97] total (95% Cl) 5.0.716 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.717 0.924 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 5.0.716 0.938 (1.17 (P = 0.004); P = 63.4% Stor overall effect Z = 1.11 (P = 0.07) tal (95% Cl) 5.0.727 0.134 4.00 4.00 10.85 [0.81, 0.96] 0.01 1.1 10 10 RAS Inhibitor		ARBs									
Bardia, 2011 -0.3857 0.0639 10.2% 0.68 [0.60,0.77] Chae, 2013 -0.5352 0.395 1.1% 0.59 [0.27, 1.27] Facciorusso, 2015 -0.9646 0.2803 2.1% 0.38 [0.22, 0.66] Karagiannis, 2014 -0.4308 0.2541 2.4% 0.05 [0.40, 1.07] Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.38, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 -0.1054 0.1488 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.4% 1.81 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] btotal (95% Cl) 44.3% 0.080 [0.47, 0.85] Holmes, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2302 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2302 2.4% 0.09 [0.50, 0.55] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 0.0701 0.3562 1.4% 2.01 [1.00, 4.05] Karagiannis, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 0.0376 0.5881 0.5% 0.38 [0.16, 1.32] Wong, 2015 0.0372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.01; Chi ² = 2.78, df = 11 (P = 0.004); I ² = 66% st for overall effect Z = 2.96 (P = 0.003) st for subcroup differences: Chi ² = 2.73, df = 1 (P = 0.10), I ² = 63.4% Encure 0. Exerce 1.04 Exerce the number of diam barree of term in antiphetion		Aydiner, 2015	-0.0101	0.3588	1.3%	0.99 [0.49, 2.00]					
Chae, 2013 -0.532 0.395 1.1% 0.59 [0.27, 1.27] Factorusso, 2015 -0.9648 0.2803 2.1% 0.38 [0.22, 0.66] Karagiannis, 2014 -0.0834 0.0344 12.1% 0.59 [0.60, 0.89] Lam, 2014 -0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.24 [0.84, 4.05] Sortch, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] btotal [95% CI] 44.3% 0.80 [0.67, 0.95] terogeneity. Tau ² = 0.04; Chi ² = 35.75, df = 10 ($P < 0.0001$); $P = 72%$ st for overall effect $Z = 2.56$ ($P = 0.01$) ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2011 0.207 0.2069 3.3% 1.22 [0.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Tuazon, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sortch, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 1.26% 0.038 [0.81, 0.96] total [95% CI] -0.078 0.0249 1.26% 0.92 [0.98, 0.97] btotal [95% CI] -0.078 0.0249 1.26% 0.92 [0.98, 0.97] btotal [95% CI] -0.078 0.0249 1.26% 0.98 [0.81, 0.96] terogeneity. Tau ² = 0.01; Chi ² = 27.99, df = 11 ($P = 0.004$); $P = 63.4\%$ tf or overall effect: $Z = 2.96$ ($P = 0.003$) st for subarou differences: Chi ² = 2.73, df = 1 ($P = 0.10$, $P = 63.4\%$ Ence 0.0 Chi c		Bardia, 2011	-0.3857	0.0639	10.2%	0.68 [0.60, 0.77]			+		
Facciorusso, 2015 -0.9648 0.2803 2.1% 0.38 [0.22, 0.66] Karagiannis, 2014 -0.0834 0.0344 12.1% 0.92 [0.86, 0.98] Lam, 2014 -0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sortch, 2016 -0.1054 0.1468 5.3% 0.09 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.20] therogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 ($P < 0.0001$); $P = 72\%$ stfor overall effect $Z = 2.56$ ($P = 0.01$) ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.09 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sortch, 2016 0.0392 0.1151 6.9% 0.124 [0.85, 1.04] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.28, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.32 [0.88, 0.87] Tuazon, 2014 -0.11 [P = 0.00]; P = 68 % st for overall effect, $Z = 2.96$ ($P = 0.003$) st for subarou differences: Chi ² = 2.7.3, df = 1 ($P = 0.10$, $P = 63.4\%$ Ence 0.6 Chered edit if the cubcheare pac		Chae, 2013	-0.5352	0.395	1.1%	0.59 [0.27, 1.27]		-			
Karagiannis, 2014 -0.0834 0.0344 12.1% 0.92 [0.86, 0.96] Lam, 2014 -0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] bitotal (95% CI) 44.3% 0.80 [0.67, 0.95] terogeneity. Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); P = 72% st for overall effect Z = 2.56 (P = 0.01) ACEIs Buchler, 2005 0.7001 0.3662 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.98 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.0476 0.5881 0.55% 0.38 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 0.97] bitotal (95% CI) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 56.52, df = 22 (P < 0.00001); I ² = 68% st for overall effect Z = 2.96 (P = 0.003) st for subaroud differences: Chi ² = 27.8, df = 11 (P = 0.10), I ² = 63.4% Ency end C = Decord eld to the outhermal or down here of color protocol publication control better		Facciorusso, 2015	-0.9648	0.2803	2.1%	0.38 [0.22, 0.66]		-			
Lam, 2014 -0.4308 0.2541 2.4% 0.65 [0.40, 1.07] Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6080 0.4031 1.1% 1.84 [0.84, 4.65] Sorich, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuzzon, 2014 0.3918 0.5335 0.6% 1.4% [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] bitotal (95% Cl) 44.3% 0.80 [0.67, 0.95] terogeneity. Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); P = 72% st for overall effect Z = 2.56 (P = 0.01) ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Gara, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.0165 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6538 0.2322 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.61, 1.32] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.0316 1.1 [P = 0.004); P = 68% st for overall effect Z = 1.11 (P = 0.27) tal (95% Cl) 10.0% 0.88 [0.81, 0.96] etrogeneity; Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.10); P = 63.4% Erwe 0.9 Excert bett to the acher and participation and participation and participation and participation and biblictors		Karagiannis, 2014	-0.0834	0.0344	12.1%	0.92 [0.86, 0.98]			-		
Osumi, 2015 -0.4943 0.2282 2.9% 0.61 [0.39, 0.95] Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] biotal (95% Cl) 44.3% 0.80 [0.67, 0.95] stor overall effect: $Z = 2.56$ ($P = 0.01$) ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Garaz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.4756 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.835 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.88, 1.64] Wong, 2015 0.078 0.2249 12.6% 0.92 [0.88, 0.97] biotal (95% Cl) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 ($P = 0.004$); $P = 63.4\%$ st for overall effect: $Z = 2.96$ ($P = 0.003$) st for subaroud differences: Chi ² = 2.73, df = 1 ($P = 0.10$); $P = 63.4\%$		Lam, 2014	-0.4308	0.2541	2.4%	0.65 [0.40, 1.07]					
Sendur, 2012 0.6098 0.4031 1.1% 1.84 [0.84, 4.05] Sorich, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.022 0.1503 5.2% 0.98 [0.73, 1.32] bibtotal (95% Cl) 44.3% 0.80 [0.67, 0.95] terogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); P = 72% st for overall effect: $Z = 2.56$ (P = 0.01) ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.00, 1.32] Karagiannis, 2014 -0.1054 0.0229 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.30 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.835 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 0.02372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 0.0249 12.6% 0.92 [0.88, 0.97] bibtotal (95% Cl) bibtotal (95% Cl) Chi ² = 27.69, df = 11 (P = 0.10), P = 63.4% Encure 0.5 Chi ² = 2.73, df = 1 (P = 0.10), P = 63.4% Encure 0.5 Chi ² = 2.73, df = 1 (P = 0.10), P = 63.4\%		Osumi, 2015	-0.4943	0.2282	2.9%	0.61 [0.39, 0.95]					
Sorich, 2016 -0.1054 0.1468 5.3% 0.90 [0.67, 1.20] Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] bitotal (95% CI) 44.3% 0.80 [0.67, 0.95] sterogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); P = 72% st for overall effect $Z = 2.56$ (P = 0.01) ACEIS Buchler, 2005 0.7001 0.3662 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2016 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1654 0.0292 12.4% 0.90 [0.85, 0.95] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.3932 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] bitotal (95% CI) 5.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.8, df = 1 (P = 0.100.); P = 63.4% st for overall effect $Z = 2.96$ (P = 0.003) st for subarous differences: Chi ² = 27.3, df = 1 (P = 0.10). P = 63.4%		Sendur, 2012	0.6098	0.4031	1.1%	1.84 [0.84, 4.05]			+		
Tuazon, 2014 0.3918 0.5335 0.6% 1.48 [0.52, 4.21] Wang, 2015 -0.0202 0.1503 5.2% 0.98 [0.73, 1.32] bibtotal (95% CI) 44.3% 0.80 [0.67, 0.95] st for overall effect: $Z = 2.56$ (P = 0.01) ACEIs Buchler, 2005 0.7001 0.3662 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Gara, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagianis, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.88, 1.64] Wong, 2015 0.017 0.577% 0.94 [0.85, 1.04] derogeneity: Tau ² = 0.01; Ch ² = 27.6.9, df = 11 (P = 0.004); P = 68% st for overall effect: $Z = 2.96$ (P = 0.003) st for subarous differences: Ch ² = 2.73. df = 1 (P = 0.10). P = 63.4% Encume 0. Encert of the two house of explose output inhibitors better Control better		Sorich,2016	-0.1054	0.1468	5.3%	0.90 [0.67, 1.20]					
Wang, 2015 -0.0202 0.1503 5.2% 0.98 $[0.73, 1.32]$ bitotal (95% CI) 44.3% 0.80 $[0.67, 0.95]$ terogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); I ² = 72% st st st for overall effect: Z = 2.56 (P = 0.01) 0.0986 0.2323 2.8% 1.10 $0.70, 1.74$ ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 $1.00, 4.05$ Chae, 2013 0.0986 0.2323 2.8% 1.10 $0.70, 1.74$ Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 $0.42, 1.04$ Ganz, 2011 0.2012 3.5% 0.89 $0.60, 1.32$ $0.73, 0.82$ Holmes, 2013 -0.165 0.0229 12.4% 0.90 0.88 $0.61, 1.32$ Karagiannis, 2014 -0.6539 0.232 2.8% 0.52 $0.33, 0.82$ 0.38 $0.16, 1.18$ Wang, 2015 0.2372 0.134 6.0% 1.27 $0.98, 0.87$ 0.94 $0.85, 1.04$ 0.01 0.01 0.01		Tuazon, 2014	0.3918	0.5335	0.6%	1.48 [0.52, 4.21]			-		
bitotal (95% CI) 44.3% 0.80 [0.67, 0.95] terogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); I ² = 72% st for overall effect: Z = 2.56 (P = 0.01) ACEIS Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 - 0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 - 0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 - 0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Limden, 2015 - 0.9876 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 - 0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.0372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.0372 0.1314 6.0% 1.27 [0.98, 1.64] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 2.96 (P = 0.003) st for subarouz differences: Chi ² = 2.78, df = 1 (P = 0.10). I ² = 63.4% Externe 0. Specie Chi ² = 2.73, df = 1 (P = 0.10). I ² = 63.4%		Wang, 2015	-0.0202	0.1503	5.2%	0.98 [0.73, 1.32]			-		
therogeneity: Tau ² = 0.04; Chi ² = 35.75, df = 10 (P < 0.0001); P = 72% st for overall effect: Z = 2.56 (P = 0.01) ACEIS Buchler, 2005 0.7001 0.3662 1.4% 2.01 (1.00, 4.05) Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.01; Chi ² = 27.69, df = 11 (P = 0.004); P = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); P = 63.4% Enume 0. Encer to lot, for the eutherceum explose of data bases of ratio actions indications output inhibitors better. Control better	u	btotal (95% CI)			44.3%	0.80 [0.67, 0.95]			•		
st for overall effect: $Z = 2.56$ (P = 0.01) ACEIs Buchler, 2005 0.7001 0.3662 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect $Z = 2.96$ (P = 0.003) st for subaroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% Encure 0.5 Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4%	e	terogeneity: Tau ² = 0.0	4; Chi ² = 35.75, df = 1	10 (P < 0.)	0001); ² =	= 72%					
ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] therogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); P ² = 68% st for overall effect: Z = 1.11 (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); P ² = 68% st for overall effect: Z = 2.96 (P = 0.003) st for subaroup differences: Chi ² = 27.3 df = 1 (P = 0.10). P ² = 63.4% Encure 0. Encure that for the publicity magnetic in the public magneti	e	st for overall effect: Z =	2.56 (P = 0.01)								
ACEIs Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] rerogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); l ² = 68% st for overall effect: Z = 2.96 (P = 0.003) st for subaroup differences: Chi ² = 2.73. df = 1 (P = 0.10). l ² = 63.4% Eigen 0. Exercise that for the outbergue percent of data baroon of rapin contact in biblictor.											
Buchler, 2005 0.7001 0.3562 1.4% 2.01 [1.00, 4.05] Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.8% 0.92 [0.88, 0.97] bitotal (95% CI) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); l ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% CI) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); l ² = 68.% st for overall effect: Z = 2.96 (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). l ² = 63.4% Eigen 0. Eigen 0.11; Chi ² = 10 or the outpergrup product of data barbon of facto batter in biblictor.		ACEIs									
Chae, 2013 0.0986 0.2323 2.8% 1.10 [0.70, 1.74] Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wang, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% st for overall effect: Z = 2.96 (P = 0.003) st for subgroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% Enume 9. Enume 9. Enume 10 for the output provide of data target of target participation and target parts in biblictore.		Buchler, 2005	0.7001	0.3562	1.4%	2.01 [1.00, 4.05]					
Facciorusso, 2015 -0.4155 0.2306 2.8% 0.66 [0.42, 1.04] Ganz, 2011 0.207 0.2069 3.3% 1.23 [0.82, 1.85] Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 1.04] Wordg, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% 0.01 0.1 10 terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 10 terogeneity: Tau ² = 0.01; Chi ² = 27.3, df = 1 (P = 0.10).		Chae, 2013	0.0986	0.2323	2.8%	1.10 [0.70, 1.74]					
Ganz, 2011 0.207 0.2069 3.3% 1.23 0.82 , 1.85 Holmes, 2013 -0.1165 0.2012 3.5% 0.89 0.60 , 1.32 Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 0.85 , 0.95 Lam, 2014 -0.6539 0.232 2.8% 0.52 0.33 , 0.82 Linden, 2015 -0.9676 0.5881 0.5% 0.38 0.12 , 1.20 Sorich, 2016 0.0392 0.1151 6.9% 1.04 0.83 , 1.30 Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 0.16 , 1.18 Wang, 2015 0.2372 0.1314 6.0% 1.27 0.98 , 1.64 Wong, 2015 -0.078 0.0249 12.6% 0.92 0.88 , 0.97 btotal (95% CI) 55.7% 0.94 0.85 , 1.04 0.01 0.1 10.1		Facciorusso, 2015	-0.4155	0.2306	2.8%	0.66 [0.42, 1.04]					
Holmes, 2013 -0.1165 0.2012 3.5% 0.89 [0.60, 1.32] Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 [0.85, 0.95] Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); P = 60% st for overall effect: $Z = 1.11$ (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); P = 68% st for overall effect: $Z = 2.96$ (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). P = 63.4% Eigen Q. Except cleic tor the outboroup on physic of down theore of control better		Ganz, 2011	0.207	0.2069	3.3%	1.23 [0.82, 1.85]					
Karagiannis, 2014 -0.1054 0.0292 12.4% 0.90 $[0.85, 0.95]$ Lam, 2014 -0.6539 0.232 2.8% 0.52 $[0.33, 0.82]$ Linden, 2015 -0.9676 0.5881 0.5% 0.38 $[0.12, 1.20]$ Sorich, 2016 0.0392 0.1151 6.9% 1.04 $[0.83, 1.30]$ Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 $[0.16, 1.18]$ Wang, 2015 0.2372 0.1314 6.0% 1.27 $[0.98, 1.64]$ Wong, 2015 -0.078 0.0249 12.6% 0.92 $[0.88, 0.97]$ biotal (95% Cl) 55.7% 0.94 $[0.85, 1.04]$ 0.94 0.88 0.97 terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% 0.94 0.94 0.88 0.91 0.01 0.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 10.1 <		Holmes, 2013	-0.1165	0.2012	3.5%	0.89 [0.60, 1.32]					
Lam, 2014 -0.6539 0.232 2.8% 0.52 [0.33, 0.82] Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% st for overall effect: Z = 2.96 (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% Eigen Q. Except cleic to the outboroup on physic of down three of control better		Karagiannis, 2014	-0.1054	0.0292	12.4%	0.90 [0.85, 0.95]			-		
Linden, 2015 -0.9676 0.5881 0.5% 0.38 [0.12, 1.20] Sorich, 2016 0.392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] btotal (95% Cl) 55.7% 0.94 [0.85, 1.04] terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: $Z = 1.11$ (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% st for overall effect: $Z = 2.96$ (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% Eigen Q. Except cleic to the outboroup on physic of down three of control better		Lam. 2014	-0.6539	0.232	2.8%	0.52 [0.33, 0.82]					
Sorich, 2016 0.0392 0.1151 6.9% 1.04 [0.83, 1.30] Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 [0.16, 1.18] Wang, 2015 0.2372 0.1314 6.0% 1.27 [0.98, 1.64] Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] ibtotal (95% CI) 55.7% 0.94 [0.85, 1.04] 1000% terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 10 tor overall effect: Z = 2.96 (P = 0.003) st for overall effect: Z = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better		Linden, 2015	-0.9676	0.5881	0.5%	0.38 (0.12, 1.20)					
Tuazon, 2014 -0.8335 0.5097 0.7% 0.43 $[0.16, 1.18]$ Wang, 2015 0.2372 0.1314 6.0% 1.27 $[0.98, 1.64]$ Wong, 2015 -0.078 0.0249 12.6% 0.92 $[0.88, 0.97]$ btotal (95% CI) 55.7% 0.94 $[0.85, 1.04]$ terogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% 100.0% 0.88 $[0.81, 0.96]$ terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 63.4% 0.01 0.1 10 terogeneity: Tau ² = 0.02; Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better		Sorich.2016	0.0392	0.1151	6.9%	1.04 [0.83, 1.30]			+		
Wang, 2015 0.2372 0.1314 6.0% 1.27 $[0.98, 1.64]$ Wong, 2015 -0.078 0.0249 12.6% 0.92 $[0.88, 0.97]$ Ibtotal (95% CI) 55.7% 0.94 $[0.85, 1.04]$ iterogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% 100.0% 0.88 $[0.81, 0.96]$ terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 10 to rowerall effect: Z = 2.96 (P = 0.003) 100.0% 0.88 $0.81, 0.96]$ 0.01 0.1 10 10 st for overall effect: Z = 2.96 (P = 0.003) RAS Inhibitors better Control better 100 st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4\% RAS Inhibitors better Control better		Tuazon, 2014	-0.8335	0.5097	0.7%	0.43 [0.16, 1.18]					
Wong, 2015 -0.078 0.0249 12.6% 0.92 [0.88, 0.97] Ibtotal (95% CI) 55.7% 0.94 [0.85, 1.04] Iterogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% CI) 100.0% 0.88 [0.81, 0.96] Iterogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 10 st for overall effect: Z = 2.96 (P = 0.003) st for subgroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better		Wang, 2015	0.2372	0.1314	6.0%	1.27 [0.98, 1.64]					
bitotal (95% CI) 55.7% 0.94 [0.85, 1.04] sterogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% CI) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 10 st for overall effect: Z = 2.96 (P = 0.003) 0.01 0.1 10 10 st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better Control better		Wong, 2015	-0.078	0.0249	12.6%	0.92 (0.88, 0.97)			-		
sterogeneity: Tau ² = 0.01; Chi ² = 27.69, df = 11 (P = 0.004); I ² = 60% st for overall effect: Z = 1.11 (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 1 10 10 st for overall effect: Z = 2.96 (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better	u	btotal (95% CI)			55.7%	0.94 [0.85, 1.04]			٠		
st for overall effect: $Z = 1.11$ (P = 0.27) tal (95% Cl) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 1 10 10 st for overall effect: $Z = 2.96$ (P = 0.003) RAS Inhibitors better Control better 10 10 st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better	e	terogeneity: Tau ² = 0.0	1: Chi ² = 27.69. df = 1	11 (P = 0)	004); I ² =	60%					
tal (95% CI) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 1 10 10 st for overall effect: Z = 2.96 (P = 0.003) st for subgroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better	e	st for overall effect: 7 =	1.11 (P = 0.27)			1.00					
tal (95% CI) 100.0% 0.88 [0.81, 0.96] terogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% 0.01 0.1 1 10 10 st for overall effect: Z = 2.96 (P = 0.003) RAS Inhibitors better Control better Control better st for subgroup differences: Chi ² = 2.73. df = 1 (P = 0.10). I ² = 63.4% RAS Inhibitors better Control better	-										
thereogeneity: Tau ² = 0.01; Chi ² = 68.52, df = 22 (P < 0.00001); I ² = 68% st for overall effect: Z = 2.96 (P = 0.003) st for suboroup differences: Chi ² = 2.73, df = 1 (P = 0.10), I ² = 63.4% Figure 9. Except plot for the subgroup enclosing of drug types of regin angiotencin system inhibitors	0	tal (95% CI)			100.0%	0.88 [0.81, 0.96]			•		
st for overall effect: Z = 2.96 (P = 0.003) st for suboroup differences: Chi ² = 2.73. df = 1 (P = 0.10). l ² = 63.4% Eiguna 9. Except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analysis of drug types of rapid analytication except plot for the suboroup analytication ex	e	terogeneity: Tau ² = 0.0	1; Chi ² = 68.52, df = 3	22 (P < 0.	00001): P	= 68%	-	-		1	
st for subaroup differences: Chi ² = 2.73. df = 1 (P = 0.10). l ² = 63.4%	e	st for overall effect: Z =	2.96 (P = 0.003)				0.01	0.1	1	10	10
Figure 9. Except plot for the subgroup analysis of drug types of rapis angiotanoin system inhibitors	e	st for subaroup differer	nces: Chi ² = 2.73 df =	= 1 (P = 0	$(10), ^2 = 6$	63.4%	RAS	s inhibitors l	oetter Control	better	
		Figure	9 Earast plat for th	o subaro		is of drug types of re-	ain angic	tonein evoto	om inhibitore		

ACEI or ARB use and cancer survival. One published metaanalysis including 11 studies indicated that ACEI or ARB use may be associated with cancer recurrence and survival.^[98] Our results are consistent with this meta-analysis. However, a number of studies published in recent years have not been included in this meta-analysis, which may obscure a true association. Another published meta-analysis only focused on breast cancer.^[99] Our



subgroup analysis by cancer types is consistent with this metaanalysis, showing no association between RAS inhibitors and survival outcomes in patients with breast cancer.

It is worth noting that RAS inhibitors are nontoxic and usually are active only in hypertensive patients while producing no adverse effects in healthy individuals. Although limited studies focused on the side effects of RAS inhibitors in cancer patients, Keizman et al^[47] reported that no inadvertent interactions were observed in patients receiving RAS inhibitors concurrently with sunitinib. In addition, there is an overwhelming body of evidence for the cardioprotection afforded by RAS inhibitor treatment.^[100] Considering the minimal side effects, relatively low costs and organ protection, more large-scale, and well designed future studies may be warranted to confirm our results, to investigate the underlying molecular mechanisms, and to define the target population that can benefit from the use of RAS inhibitors.

In conclusion, our findings showed that RAS inhibitor use was associated with cancer progression and survival. Cancer type and type of RAS inhibitor can influence the association between RAS inhibitor use and OS in cancer patients, while ethnicity had no influence. We believe that our results have great significance to guide clinical rational drug use of antihypertensive agents in cancer patients with hypertension. For further verification of our results, more large-scale and well designed studies are warranted.

References

- Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol 2016;7:249–57.
- [2] Yacoub R, Campbell K. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis 2015;15:29–40.
- [3] Meier C, Derby L, Jick S, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349–53.
- [4] Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010;103:1644–8.
- [5] Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 2009;23:623–35.
- [6] Nakai Y, Isayama H, Sasaki T, et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer. Pancreas 2013;42:202–8.
- [7] Osumi H, Matsusaka S, Suenaga M, et al. Angiotensin II receptor blocker (ARB) may have a synergic effect in metastatic colorectal cancer (MCRC) patients treated with bevacizumab (BEV). Ann Oncol 2013;24(supp. 14):PD0027.
- [8] Herr D, Bekes I, Wulff C. Renin–Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 2013;4:1–7.
- [9] Herichova I, Szantoova K. Renin–angiotensin system upgrade of recent knowledge and perspectives. Endocr Regul 2013;47:39–52.
- [10] Carey R. The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure. Hypertension 2013;61:673–80.
- [11] Bader M, Ganten D. Update on tissue renin–angiotensin systems. J Mol Med 2008;86:615–21.
- [12] Beyazit Y, Purnak T, Suvak B, et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol 2011;35:644–9.
- [13] Arrieta O, Villarreal-Garza C, Vizcaíno G, et al. Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumour Biol 2015;36: 5627–34.
- [14] Röcken C, Röhl FW, Diebler E, et al. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;6: 1206–12.
- [15] Arrieta O, Pineda-Olvera B, Guevara-Salazar P, et al. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 2008;99:160–6.
- [16] Greco S, Muscella A, Elia M, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 2003;196:370–7.
- [17] Egami K, Murohara T, Shimada T, et al. Role of hostangiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003;112:67–75.
- [18] Roscioni S, Heerspink H, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2014;10: 77–87.
- [19] Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294:441–7.
- [20] Neo J, Malcontenti-Wilson C, Muralidharan V, et al. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007;22: 577–84.
- [21] Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- [22] Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 1998;17:2815–34.
- [23] Tierney J, Stewart L, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
- [24] Abouelezz K, Kaseb A, Hassabo H, et al. Prognostic effect of angiotensin-converting-enzyme inhibitors in HCC patients treated with sorafenib. J Clin Oncol 2013;31:328.
- [25] Aydiner A, Ciftci R, Sen F. Renin–angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine 2015;94:e887.

- [26] Babacan T, Balakan O, Kuzan TY, et al. The effect of reninangiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON 2015;20:50–6.
- [27] Bardia A, Cowan J, Carroll P, et al. Association of angiotensin II blockers with survival among men with prostate cancer results from CaPSURE. J Clin Oncol 2011;29: (15_suppl, abstr 4538).
- [28] Blute M, Rushmer T, Shi F, et al. Renin-angiotensin inhibitors decrease recurrence after TURBT in non-muscle invasive bladder cancer. J Urology 2015;194:1214–9.
- [29] Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 2014;144:405–16.
- [30] Buchler T, Krejci M, Svobodnik A, et al. Outcome of patients with multiple myeloma and hypertension treated with angiotensin-Iconverting enzyme inhibitors during high-dose chemotherapy. Hematol J 2005;5:559–64.
- [31] Cardwell C, Mc MU, Hicks B, et al. Drugs affecting the reninangiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med 2014;12:28.
- [32] Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011;29:585–93.
- [33] Chae YK, Brown EN, Lei X, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 2013;4:549–56.
- [34] Chae YK, Dimou A, Pierce S, et al. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma 2014;55:2822–9.
- [35] Chen Y, Huang C, Lu H, et al. Prognostic impact of renin–angiotensin system blockade in esophageal squamous cell carcinoma. J Renin Angiotensin Aldosterone Syst 2015;16:1185–92.
- [36] Derosa L, Izzedine H, Le Teuff G, et al. Impact of angiotensin system inhibitors (ASI) on outcome in sunitinib (SU)-treated patients for metastatic renal cell carcinoma (mRCC) Gustave Roussy experience. J Clin Oncol 2014;32: (suppl; abstr 4584).
- [37] Engineer DR, Burney BO, Hayes TG, et al. Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol 2013;6:539–45.
- [38] Facciorusso A, Del Prete V, Crucinio N, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroen Hepatol 2015;30:1643–50.
- [39] Failing JJ, Finnes HD, Kottschade LA, et al. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res 2016;26:609–15.
- [40] Fujii T, Takahashi O, Teruo Y. ACE inhibitors/ARB and the risk of breast cancer recurrence after surgery in Japanese population A pilot study. J Clin Oncol 2012;30: (suppl 27; abstr 52).
- [41] Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549–56.
- [42] He L, Qiao W, Liao Z, et al. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer 2015;15:111.
- [43] Holmes MD, Hankinson SE, Feskanich D, et al. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 2013;139:507–13.
- [44] Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015;26:1128–33.
- [45] Januel E, Ursu R, Alkhafaji A, et al. Impact of renin–angiotensin system blockade on clinical outcome in glioblastoma. Eur J Neurol 2015;22:1304–9.
- [46] Karagiannis T, Keith S, Rabinowitz C, et al. Investigating survival associated with angiotensin blockade agents in patients with pancreatic cancer. Value Health 2014;17:A71–2.
- [47] Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 2011;47:1955–61.
- [48] Keizman D, Gottfried M, Ish-Shalom M, et al. Active smoking may negatively affect response rate, progression-free survival, and overall

survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014;19:51–60.

- [49] Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin–angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy. Oncology 2012;83:354–60.
- [50] Kumekawa Y, Wakatsuki T, Osumi H, et al. ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin. J Clin Oncol 2015;33: (suppl 3; abstr 174).
- [51] Lam A, Allen J, Srinivas S. Timing of angiotensin system inhibitor use and overall survival in patients on tyrosine kinase inhibitors for renal cell carcinoma. J Clin Oncol 2014;32:e15587.
- [52] Linden C, Redman R, Rai S, et al. Effect of angiotensin converting enzyme inhibition on outcomes in patients with head and neck squamous cell carcinoma. J Invest Med 2015;63:469.
- [53] Magnuson W, Morris Z, Mohindra P, et al. Potential influence of ace inhibitors and angiotensin receptor blockers on outcome in patients with oropharynx cancer treated with radiation therapy. Int J Radiat Oncol 2014;1:S516–7.
- [54] McKay R, Rodriguez G, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21:2471–9.
- [55] Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645–52.
- [56] Menter A, Carroll N, Sakoda L, et al. Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer 2016;S1525-7304: 30187–8.
- [57] Miao L, Chen W, Zhou L, et al. Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC. Sci Rep 2016;6:21359.
- [58] Miyajima A, Yazawa S, Kosaka T, et al. Prognostic impact of renin–angiotensin system blockade on renal cell carcinoma after surgery. Ann Surg Oncol 2015;22:3751–9.
- [59] Morris ZS, Saha S, Magnuson WJ, et al. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensinconverting enzyme inhibitors or angiotensin receptor blockers. Cancer 2016;122:2487–95.
- [60] Nakai Y, Isayama H, Sasaki T, et al. The inhibition of reninangiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. J Cancer Res Clin 2015;141:933–9.
- [61] Nakai Y, Isayama H, Sasaki T, et al. No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer. Anticancer Res 2016;36:4965–70.
- [62] Ole-Petter RH, Choueiri TK, Turchin A, et al. Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is). J Clin Oncol 2014;32: (suppl; abstr 9639).
- [63] Osumi H, Matsusaka S, Wakatsuki T, et al. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol 2015;3:1295–300.
- [64] Ranasinghe W, Williams S, Sengupta S, et al. Effects of angiotensinconverting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC). J Clin Oncol 2013;31: (suppl; abstr e16016).
- [65] Ronquist G, Frithz G, Wang YH, et al. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol 2009;43:32–6.
- [66] Sendur M, Aksoy S, Yaman S, et al. Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer. Breast 2012;21:419–20.
- [67] Sha P, Tsai J, Hsieh K. Cancer prognosis following the usage of angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers on lung cancer patients with hypertension history. Pharmacoepidemiol Drug Saf 2014;23:376.
- [68] Holmes S, Griffith EJ, Musto G, et al. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol 2013;37:881–5.
- [69] Sorensen G, Ganz P, Cole S, et al. Use of β-blockers, angiotensinconverting enzyme inhibitors, angiotensin ii receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 2013;31:2265–72.

- [71] Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin–angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer 2012;106:290–6.
- [72] Tuazon S, King G, Cruz J, et al. Angiotensin converting enzyme inhibitor and angiotensin receptor blocker use and outcomes in patients with colorectal cancer. J Clin Oncol 2014;32: (suppl 3; abstr 544).
- [73] Wang H, Liao Z, Zhuang Y, et al. Incidental receipt of cardiac medications and survival outcomes among patients with stage III nonsmall-cell lung cancer after definitive radiotherapy. Clin Lung Cancer 2015;16:128–36.
- [74] Wilop S, von Hobe S, Crysandt M, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin 2009;135:1429–35.
- [75] Wong MC, Tam WW, Lao X, et al. The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study. Int J Cardiol 2015;179:178–85.
- [76] Yoshida T, Kinoshita H, Fukui K, et al. Prognostic impact of renin–angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol 2017;24:823–31.
- [77] Yoshiji H, Noguchi R, Ikenaka Y, et al. Combination of branchedchain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011;26:1547–53.
- [78] Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of renin–angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol 2012;19:3987–93.
- [79] Daemen MJ, Lombardi DM, Bosman FT, et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450–6.
- [80] Buharalioglu CK, Song CY, Yaghini FA, et al. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol 2011;301:H1043–55.
- [81] Yang X, Zhu MJ, Sreejayan N, et al. Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparinbinding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 2005;20:263–70.
- [82] Tamarat R, Silvestre J-S, Durie M, et al. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Investig J Tech Methods Pathol 2002;82:747–56.
- [83] Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141–5.
- [84] Chiu T, Santiskulvong C, Rozengurt E. ANG II stimulates PKC dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G1–1.
- [85] Li SH, Lu HI, Chang AY, et al. Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation. Oncotarget 2016;7:67150–65.
- [86] Dolley-Hitze T, Jouan F, Martin B, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103:1698–705.
- [87] Han CD, Ge WS. Up-regulation of angiotensin-converting enzyme (ACE) enhances cell proliferation and predicts poor prognosis in laryngeal cancer. Med Sci Monit 2016;22:4132–8.
- [88] Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007;67:41–9.
- [89] Escobar E, Rodríguez-Reyna TS, Arrieta O, et al. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004;2:385–99.
- [90] Uemura H, Nakaigawa N, Ishiguro H, et al. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 2005;5:307–23.
- [91] Hii SI, Nicol DL, Gotley DC, et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880–3.

- [92] Ishiguro H, Ishiguro Y, Kubota Y, et al. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007;67:924–32.
- [93] Funao K, Matsuyama M, Kawahito Y, et al. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 2008;20:295–300.
- [94] Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl 2014;16:372–7.
- [95] Pokuri VK, Tomaszewski GM, Ait-Oudhia S, et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): phase II trial. Am J Clin Oncol 2016; doi:10.1097/COC.00000000000286. [Epub ahead of print].
- [96] Chen LT, Oh DY, Ryu MH, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a

systematic review. Cancer Res Treat 2017;doi:10.4143/crt.2016.176. [Epub ahead of print].

- [97] Wen J, Li HZ, Ji ZG, et al. Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro. Chin Med Sci J 2015;30:51–5.
- [98] Song T, Choi CH, Kim MK, et al. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis. Eur J Cancer Prev 2017;26:78–85.
- [99] Raimondi S, Botteri E, Munzone E, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and metaanalysis. Int J Cancer 2016;139:212–9.
- [100] von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 2013;27: 171–9.